Redhill Biopharma Ltd
RDHL1.210USD
+0.010+0.83%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
1.56MValor de mercado
0.13P/L TTM
Mais detalhes de Redhill Biopharma Ltd Empresa
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Informações da empresa
Código da empresaRDHL
Nome da EmpresaRedhill Biopharma Ltd
Data de listagemFeb 01, 2011
CEOMr. Dror Ben-Asher
Número de funcionários35
Tipo de títulosDepository Receipt
Fim do ano fiscalFeb 01
Endereço21 Ha'arba'a St.
CidadeTEL AVIV-YAFO
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísIsrael
Código postal6473921
Telefone97235413131
Sitehttps://www.redhillbio.com/
Código da empresaRDHL
Data de listagemFeb 01, 2011
CEOMr. Dror Ben-Asher
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
Ms. Patricia Anderson
Ms. Patricia Anderson
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Razi Ingber
Mr. Razi Ingber
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexandra Okmian
Mr. Alexandra Okmian
Investor Relations
Investor Relations
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Reza Fathi, Ph.D.
Dr. Reza Fathi, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
--
--
Mr. Ofer Tsimchi
Mr. Ofer Tsimchi
Independent Director
Independent Director
--
--
Dr. Kenneth Reed, M.D.
Dr. Kenneth Reed, M.D.
Independent Director
Independent Director
--
--
Mr. Guy Goldberg, J.D.
Mr. Guy Goldberg, J.D.
Chief Business Officer
Chief Business Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Shmuel Cabilly, Ph.D.
Dr. Shmuel Cabilly, Ph.D.
Independent Director
Independent Director
--
--
Ms. Patricia Anderson
Ms. Patricia Anderson
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Razi Ingber
Mr. Razi Ingber
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alexandra Okmian
Mr. Alexandra Okmian
Investor Relations
Investor Relations
--
--
Mr. Adi Frish
Mr. Adi Frish
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
--
--
Mr. Dror Ben-Asher
Mr. Dror Ben-Asher
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 2 de jul
Atualizado em: qua, 2 de jul
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Heights Capital Management, Inc.
3.05%
Citadel Advisors LLC
0.94%
Desjardins Securities Inc.
0.15%
GAMMA Investing LLC
0.09%
Rhumbline Advisers Ltd. Partnership
0.06%
Other
95.72%
Investidores
Investidores
Proporção
Heights Capital Management, Inc.
3.05%
Citadel Advisors LLC
0.94%
Desjardins Securities Inc.
0.15%
GAMMA Investing LLC
0.09%
Rhumbline Advisers Ltd. Partnership
0.06%
Other
95.72%
Tipos de investidores
Investidores
Proporção
Investment Advisor
3.11%
Hedge Fund
0.94%
Research Firm
0.16%
Investment Advisor/Hedge Fund
0.09%
Other
95.70%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
39
98.72K
4.30%
-26.30K
2025Q1
45
100.27K
5.67%
-27.27K
2024Q4
61
86.70K
6.77%
-35.73K
2024Q3
77
75.64K
5.91%
-52.57K
2024Q2
82
147.72K
11.56%
-10.64K
2024Q1
84
175.94K
13.78%
+109.25K
2023Q4
94
19.30K
14.67%
-65.78K
2023Q3
106
74.17K
44.30%
+53.53K
2023Q2
113
26.79K
29.96%
+840.00
2023Q1
122
24.63K
29.02%
+7.31K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Heights Capital Management, Inc.
70.00K
3.05%
+70.00K
--
Jan 25, 2024
Citadel Advisors LLC
21.51K
0.94%
+21.51K
--
Mar 31, 2025
Desjardins Securities Inc.
3.39K
0.15%
--
--
Mar 31, 2025
GAMMA Investing LLC
3.57K
0.16%
-1.52K
-29.89%
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
1.39K
0.06%
+190.00
+15.86%
Mar 31, 2025
BofA Global Research (US)
303.00
0.01%
+301.00
+15050.00%
Mar 31, 2025
Group One Trading, L.P.
22.00
0%
--
--
Mar 31, 2025
Yorkville Asset Management, Inc.
14.00
0%
--
--
Sep 30, 2024
Morgan Stanley & Co. LLC
11.00
0%
-2.20K
-99.50%
Mar 31, 2025
FMP Wealth Advisers
47.00
0%
+47.00
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Aug 06, 2024
Merger
25<1
Aug 06, 2024
Merger
25<1
Aug 06, 2024
Merger
25<1
Aug 06, 2024
Merger
25<1
Mar 17, 2023
Merger
40<1
Mar 17, 2023
Merger
40<1
Data
Tipo
Proporção
Aug 06, 2024
Merger
25<1
Aug 06, 2024
Merger
25<1
Aug 06, 2024
Merger
25<1
Aug 06, 2024
Merger
25<1
Mar 17, 2023
Merger
40<1
Mar 17, 2023
Merger
40<1
Mar 17, 2023
Merger
40<1
Mar 17, 2023
Merger
40<1
